Michael A. Gold
Expertise in
27
conditions

Dr. Michael A. Gold

Gynecologic Oncology | Oncology
Oklahoma Cancer Specialists And Research Institute, LLC
12697 E 51st St, 
Tulsa, OK 
38 Years of Experience
Expertise in
27
conditions
Oklahoma Cancer Specialists And Research Institute, LLC
12697 E 51st St, 
Tulsa, OK 

Overview

Michael Gold is a Gynecologic Oncologist and an Oncologist practicing medicine in Tulsa, Oklahoma. He has been practicing medicine for over 38 years.

Dr. Gold is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Cervical Cancer, Vulvar Cancer, Bladder Reconstruction, and Hernia Surgery.

He is actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 11 clinical trials.

Graduate Institution

Jefferson Medical College Of Thomas Jefferson University, 1988

Residency

Thomas Jefferson University Hospital, Inc.

Specialties

Gynecologic Oncology
Oncology

Licenses

Obstetrics & Gynecology in OK

Fellowships

University of Oklahoma College of Medicine - 1996

Hospital Affiliations

Ascension St John Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
CommunityCare
  • HMO
GlobalHealth
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
12697 E 51st St, Tulsa, OK 74146

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Terminated
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: March 24, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer
A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 28, 2025
Intervention Type: Biological
Study Drug: AK104
Study Phase: Phase 2
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drug: Prexasertib
Study Phase: Phase 2
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

51 Total Publications

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.
Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.
Journal: Future oncology (London, England)
Published: April 07, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Katherine M. Moxley
Gynecologic Oncology | Obstetrics and Gynecology | Orthopedics
Expertise in
17
conditions
Dr. Katherine M. Moxley
Gynecologic Oncology | Obstetrics and Gynecology | Orthopedics

Oklahoma State University

2345 Southwest Blvd, 
Tulsa, OK 
 (10.0 miles away)
918-561-5701
Experience:
26+ years
Languages Spoken:
English
See accepted insurances

Katherine Moxley is a Gynecologic Oncologist and an Obstetrics and Gynecologist practicing medicine in Tulsa, Oklahoma. She has been practicing medicine for over 26 years. Dr. Moxley is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Vulvar Cancer, Hysterectomy, and Gastrostomy.

Expertise in
15
conditions
Dr. Alfred D. Jenkins
Gynecologic Oncology | Oncology | Surgical Oncology
Expertise in
15
conditions
Dr. Alfred D. Jenkins
Gynecologic Oncology | Oncology | Surgical Oncology

Oklahoma Cancer Specialists And Research Institute, LLC

12697 E 51st St, 
Tulsa, OK 
 (0.1 miles away)
918-505-3200
Experience:
33+ years
Languages Spoken:
English
See accepted insurances

Alfred Jenkins is a Gynecologic Oncologist and an Oncologist practicing medicine in Tulsa, Oklahoma. He has been practicing medicine for over 33 years. Dr. Jenkins is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Vulvar Cancer, Lump in the Abdomen, Malignant Mixed Mullerian Tumor, Oophorectomy, and Salpingo-Oophorectomy.

Expertise in
13
conditions
Dr. Daron G. Street
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
13
conditions
Dr. Daron G. Street
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Oklahoma Cancer Specialists And Research Institute, LLC

12697 E 51st St, 
Tulsa, OK 
 (0.1 miles away)
918-505-3200
Experience:
40+ years
Languages Spoken:
English
See accepted insurances

Daron Street is a Gynecologic Oncologist and an Oncologist practicing medicine in Tulsa, Oklahoma. He has been practicing medicine for over 40 years. Dr. Street is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Malignant Mixed Mullerian Tumor, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Hernia Surgery, and Oophorectomy.

Frequently Asked Questions about Dr. Michael A. Gold

How do I make an appointment with Dr. Michael A. Gold?

You can book an appointment with Dr. Michael A. Gold by calling their office at 918-505-3200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael A. Gold a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael A. Gold is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael A. Gold specialize in?

While Dr. Michael A. Gold is a Gynecologic Oncology, they have specific expertise in Endometrial Cancer, Cervical Cancer, and Vulvar Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gynecologic Oncology.

Does Dr. Michael A. Gold participate in research or clinical trials?

Yes. Dr. Michael A. Gold has published 51 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Michael A. Gold's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael A. Gold accept my insurance?

Dr. Michael A. Gold accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 918-505-3200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gold's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 14 Advanced Conditions
View All 66 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile